Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Saturday. The firm issued a sell rating on the stock.

Several other equities research analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.

Can-Fite BioPharma Price Performance

NYSE:CANF opened at $1.55 on Friday. The firm has a market cap of $5.49 million, a PE ratio of -0.87 and a beta of 1.36. The firm has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $2.26. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC increased its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.